|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: EGF-R Agonists and Antagonists
La Merie, Sep 2009, Pages: 66
The present Competitive Intelligence Report about EGF-R agonists and antagonists provides a competitor evaluation in the field of epidermal growth factor receptor (EGF-R; ErbB1) targeting molecules for wound healing or treatment of cancer as of September 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The human epidermal growth factor receptor (HER) family members include EGFR (erbB1), HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4) that are structurally related, and all except HER3 contain intracellular tyrosine kinase (tk) domain. All of the HER members, except HER2, bind to extracellular ligands
EGFR, a valid target in many epithelial malignancies, is a transmembrane protein with an extracellular ligand binding domain joined to an intracellular tyrosine kinase domain. Activation of EGFR induces a cascade of downstream signaling through several pathways, such as mitogenac tivated protein kinase (MAPK) and PI3-kinase / Akt/mTOR, resulting in cellular proliferation, differentiation, survival, motility, adhesion, and repair. EGFR is overexpressed or abnormally activated in several epithelial malignancies. Several antibodies targeting EGF-R and small molecules inhibiting the EGF-R tyrosine kinase have been approved and are used for treatment of colorectal cancer, squamous cell cancer of the head & neck or pancreatic cancer, respectively. EGF-R targeting therapeutics achieved 2008 sales of US$ 3.35 bln.
The pipeline of novel EGF-R targeting molecules is rather full and includes novel antibody as well as vaccine approaches and small molecules with a broader inhibition profile. At least six next generation antibodies against EGF-R are already in clinical development and more than ten biologics are preclinical R&D including dual target antibodies or vaccines. The small molecule pipeline is focused on dual EGF-R and Her2 as well as pan-Her tk inhibitors, but also includes multi-target EGF-R tk inhibitors.
The report includes a compilation of current active projects in research and development of molecules targeting the EGF receptor. In addition, the report lists company-specific R&D pipelines of EGF-R targeting small molecules, antibodies, proteins, cells and vaccines. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Competitor Analysis: Her2 Receptor Antagonists
Competitor Analysis: FGF-R Agonists and Antagonists
Competitor Analysis: PDGF-R Agonists and Antagonists
Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists
Competitor Analysis: TGF-R Agonists and Antagonists
Competitor Analysis: CXCR and CXCL Agonists and Antagonists
Competitor Analysis: IGF-1R Antagonists
Competitor Analysis VEGF and VEGF-R Agonists and Antagonists
Competitor Analysis: Muscarinic Receptor Agonists & Antagonists
Interleukin-6 (IL-6) and Receptor (IL-6R) Antagonists
Brief Report: CD40 and CD40L (CD154) Agonists and Antagonists
Competitor Analysis: EpCAM Antagonists
|
|
|
|
